In early February, the U.S. Federal Trade Commission published a proposed order that fines telehealth and discount prescription provider GoodRX $1.5 milllion. Though part of the case involves deception — one of two prongs under the FTC Act — the case also raises the first-of-its-kind use of the Health Breach Notification Rule. To help better understand the novel and complex issues embedded in the case, IAPP Editorial Director Jedidiah Bracy, CIPP, caught up with WilmerHale Partner Kirk Nahra, CIPP/US, to discuss some of the takeaways privacy pros in any industry vertical should consider.
Listen Here
10 Feb. 2023
Top takeaways from the FTC-GoodRx case: A chat with Kirk Nahra
Related stories
Notes from the IAPP Canada: Consultation period on CBPR implementation ends 30 June
CPPA Board tees up new consultation on draft ADMT, cybersecurity audit, risk assessment regulations
Ireland's DPC finalizes TikTok decision with potential data transfer ban
A view from DC: Colorado considers re-forging AI guardrails
Biometric promises, regulatory gaps: Why Canada needs a new approach to facial recognition technology
This article is eligible for Continuing Professional Education credits. Please self-submit according to CPE policy guidelines.